biols

4 ms·

1.
by biols 4y ago
Yes!! I and my colleagues and probably everyone I went to graduate school with would love a resource like that. I'd be happy to help promote and/or contribute articles / papers I'm reading
2.
by biols 4y ago
Side question: does anybody know of a Hacker News type aggregator for biotech which isn't fuddy-duddy or paid? Sites like STAT+ and Fierce Biotech usually feel more focused on business concerns ("Company X just got $Y in their ser
3.
by biols 4y ago
Putting "gay-everything in your face at every corner" next to "obvious hard core drug abuse on the sidewalks" could be misconstrued as homophobic, which I hope wasn't your intention, especially during pride month.
4.
by biols 5y ago
I'd be very happy to participate in those type of projects. One could even imagine that pharma companies could be _mandated_ to spend a certain number of people-hours on R&D in a research collaborative.
5.
by biols 5y ago
I agree that the system is just "reality" right now. I think the idea of a cryptographic data commons is an interesting idea, I'm just trying to imagine how it'd play out in my day-to-day research. If a system would tell
6.
by biols 5y ago
I think the idea would have been that Pfizer and Moderna could have pooled resources and made a single optimal vaccine faster, though I'll admit I'm not sure it could have happened any faster than it did from my perspective. The K
7.
by biols 5y ago
The Broad Institute hosts a very interesting transcriptomic dataset called CMap [1] that was intended to facilitate rapid drug repurposing. Having studied this dataset and worked with the data generators and software teams, I can say that d
8.
by biols 5y ago
This is what I'd like to see. There should be some kind of system where in-progress research being done by pharma companies can be published. This would reduce the massively redundant amount of studies (e.g. CRISPR screens, xenograft s
9.
by biols 5y ago
Major pharma companies are all constantly competing, and very often are duplicating work because they are not sharing major experimental results. The way it feels is that there's already "too many people" working in certain a
10.
by biols 5y ago
I work at a medium-sized pharmaceutical company as a computational biologist. Diseases like KS sometimes come up as potential repurposing targets (or novel drug targets), but we get a LOT of pushback from finance / leadership because w
11.
by biols 8y ago
There's the 20/20/20 rule (every 20 minutes, look at something 20 feet away for 20 seconds) that's cited often. I started to have similar issues, and my optometrist set me up with some reading glasses optimized for how f